Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: A multicentre experience in antiretroviral therapy-naive and -experienced patients

D. Podzamczer, A. Imaz, I. Perez, P. Viciana, E. Valencia, J. Curto, T. Martín, M. Castaño, J. Rojas, N. Espinosa, V. Moreno, V. Asensi, J. A. Iribarren, B. Clotet, L. Force, P. Bachiller, H. Knobel, J. C. López Bernaldo De Quirós, J. R. Blanco, N. RozasJ. Vergas, A. Ocampo, A. Camacho, J. Flores, J. L. Gomez-Sirvent

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)


Objectives: To present clinical experience with a regimen including abacavir/lamivudine+darunavir/ritonavir in a cohort of HIV-1-infected patients. Methods: A retrospective, multicentre cohort study, including all consecutive adult HIV-1-infected patients who started abacavir/lamivudine+darunavir/ritonavir from April 2008 to December 2010 and had at least one followup visit. The primary endpoint was HIV-1 viral load (VL) <40 copies/mL at week 48. Results: One hundred and eighty-three patients (42 naive and 141 experienced) from 19 hospitals in Spain were studied. The median follow-up was 26.7 (0.5-58.6) months, 79.8% were men, the median age was 47.1 (21.4- 80.5) years, 26.2% had AIDS and 38.8% were positive for hepatitis C virus. At baseline, the median CD4 count was 246 cells/mm3 in naive patients and 393 cells/mm3 in experienced patients and the median VL was 4.80 and <1.59 log copies/mL, respectively. Atweek 48, 81.8% of naive patients and 84.2% of experienced patients receiving the regimen reached a VL <40 copies/mL, whereas at 96 weeks this occurred in 90.5% and 92.8%, respectively. CD4 cell count increases at 48 and 96 weeks were +176.5 and +283.5 cells/mm3 in naive patients and +74.9 and +93 cells/mm3 in experienced patients, respectively. Overall, 86 (47%) patients discontinued the study regimen, in many cases possibly related to non-medical reasons, such as drug switches to reduce cost or changes in address due to economic constraints. Three patients died of causes unrelated to therapy and 19 (10.4%) discontinued the regimen due to adverse events. Conclusions: In our cohort, abacavir/lamivudine+darunavir/ritonavir was safe, well tolerated and achieved high rates of virological suppression. In a proportion of patients, discontinuation of this effective regimen was possibly due to non-medical reasons. © The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
Original languageEnglish
Article numberdku157
JournalJournal of Antimicrobial Chemotherapy
Issue number9
Publication statusPublished - 1 Jan 2014


  • HIV treatment
  • Protease inhibitors
  • Viral response

Fingerprint Dive into the research topics of 'Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: A multicentre experience in antiretroviral therapy-naive and -experienced patients'. Together they form a unique fingerprint.

Cite this